Executive Council

President
G. Frank Gerberick, Ph.D.
Procter & Gamble
gerberick.gf@pg.com

President-Elect
James E. Riviere, DVM, Ph.D.
North Carolina State University
jim_riviere@ncsu.edu

Vice-President
Ian Kimber, Ph.D.
Syngenta
ian.kimber@syngenta.com

Secretary-Treasurer
Jeffrey D. Laskin, Ph.D.
UMDNJ - Robert Wood Johnson
Medical School
laskin@eohsi.rutgers.edu

Counselors
Diane A. Heck, Ph.D.
Rutgers University
dheck@eohsi.rutgers.edu

Elena A. Serbinova, Ph.D.
Penederm Incorporated
eserbinova@penederm.com

B. Jean Meade, Ph.D.
CDC/NIOSH
bhm8@cdc.gov

President’s Message

The first year of the Dermal Toxicology Specialty Section was a tremendous success. Most of the success we have had is due in large part to the efforts of our first President, Anna A. Shevedova, who demonstrated great leadership in forming the foundation of our specialty section. As of June, 2001 DTSS has 64 paid members. In just one year, we have established 7 functioning committees and developed a newsletter and website to communicate with our membership. At this year’s meeting the DTSS sponsored its first symposium, entitled "Phenolic Compounds: Free Radical Mechanisms of Toxicity, Catalysis, and Protection." The session was well attended and was successful in elaborating our current understanding of specific free radical mechanisms responsible for different toxic and/or functional roles and pathways of phenolic compounds in cells. All of this in just one year! Again, our sincere thanks to Anna for all her efforts in getting DTSS off to such a great start.

The executive council’s number one priority for the coming year is to build the DTSS’s membership by at least 50%. Working with Guilin Qiao and others on the Membership Committee, we plan to develop an active recruiting strategy to help build our membership. The membership distribution is currently Industry, 69%; Government, 17%; Academia, 11%; and Other, 3%. A specific goal of the Membership Committee will be to build our membership with scientists from Government and Academia. A number of membership activities will be initiated over the coming year and it is our hope that all DTSS members will help us reach our membership goal.

Another key priority for the coming year is to develop a very active Program Committee. We are pleased to announce that DTSS will be co-sponsoring a symposium entitled, “Altered Gene Expression and Cutaneous Toxicity” at next year’s SOT meeting in Nashville, TN. To build a strong presence at SOT, we will need to have a very active and productive DTSS Program Committee. Our goal will be to have this committee start early (late fall) in planning a strong list of potential continuing education courses, symposium and workshops to share with SOT’s Program Committee next year in Nashville. There is no doubt that having a successful program committee will be helpful in directly building the reputation and membership of DTSS. Jim E. Riviere, President-Elect, will lead our Program Committee for the coming year. Jim has considerable experience in developing successful SOT programs.

I want to acknowledge the hard work of Mike Robinson and Lisa Ryan who have developed our outstanding DTSS newsletter. The newsletter serves as a source of information on our committee’s activities and accomplishments as well as a communication tool on the activities of individual members (e.g., publications, position announcements). This communication tool is critical to our success and I asked each of you to submit information that you think would be valuable to our DTSS membership.

Finally, congratulations to Ian Kimber who was elected DTSS Vice-President Elect for 2001-2002.

I’m looking forward to us having a great year in developing the DTSS to become bigger and stronger. It is my hope that each of you will help us grow DTSS into one of SOT’s most successful specialty sections.

G. Frank Gerberick
gerberick.gf@pg.com
Committee Updates

Membership Committee
Submitted by Guolin Qiao

Since the 2001 SOT annual meeting, the Committee and its Chair, Dr. Qiao and the new DTSS president Dr. Gerberick have been working on the enhancement of the membership drive activities. The committee will closely work with the DTSS to maintain a minimum of 50 official members in order to keep the new subspecialty section viable during this critical stage. Additionally, continual effort will be directed towards membership record keeping/updating. Increased energy will be directed at recruitment of DTSS members from the skin toxicology communities in academia and other countries. The committee also wants to encourage DTSS officials/members to play a greater role in the membership drive in the near future. We will develop an electronic version of the DTSS membership list and then update the DTSS webpage information as frequently as possible. As of May 30, 2001, the DTSS has 64 paid members. Membership distribution was characterized as Industry 69%, Federal Government 17%, University 11%, and Others 3%. Some membership applications are still in process and we are expecting an increase in near future.

With the progressing maturity of our DTSS, several issues have required attention. The first is improving communication between DTSS and SOT-HQ with regards to an accurate membership roster. The listing above is our most recent and accurate registered DTSS membership list and we have created an email list for information distribution purposes.

The second issue is expanding our membership. To grow DTSS membership, we are asking all registered members of DTSS to provide the membership committee with the names of potential members along with their email addresses and phone numbers. Our committee will contact these individuals for recruitment into the DTSS. The academic sector is currently under represented. We need your help! So, please think about DTSS officials/members to play a greater role in the membership drive in the near future. We will develop an electronic version of the DTSS membership list and then update the DTSS webpage information as frequently as possible. As of May 30, 2001, the DTSS has 64 paid members. Membership distribution was characterized as Industry 69%, Federal Government 17%, University 11%, and Others 3%. Some membership applications are still in process and we are expecting an increase in near future.

The third issue relates to the authorized use of the DTSS membership roster. Following discussion among the DTSS president and the chairs of the membership and communications committees, it was decided to recommend an email directory usage policy modified from one proposed by another specialty subsection. The following guidelines have been recommended.

1. The list shall not be used for job solicitation purposes - either for those seeking employment or those seeking to fill positions.
2. Access to the list shall be limited to only a few Executive Committee Members- this would include the President, Vice-President, and Secretary/Treasurer as well as the heads of Membership and Communications.
3. The list, while not proprietary, will not be made available to non-members for any reason.
4. All messages requested to be mass e-mailed shall first be approved by the President or his/her representative.
5. The list shall, in conjunction with Membership, be maintained by the Communications Chair.
6. All members will be given the opportunity to opt out of the listing.
7. The list shall be used for queries of entire membership (for example, requests by the Program Committee for ideas for presentations at upcoming national meetings) or for dissemination of important information to all (such as upcoming meetings of interest, funding opportunities, newsletter distribution, etc.).
8. Usage of the list by the student representative shall be governed by the same rules as above. All messages requested to be mass e-mailed should be sent to the Communications Chair, who will then forward the requests to the President for approval.

We look forward to your comments on our recommendations.

Lastly, the membership committee welcomes a new member, Cynthia A. Ryan, BS, MT (ASCP) from The Procter & Gamble Company, who will work, as a committee member, with our existing members Guolin Qiao (Chair), NIOSH/CDC, Brian Jones (Co-Chair), Avon Product Inc., and Rick P. Moody (member), Health Canada.

Guolin Qiao, Chair
GAQ1@CDC.gov
Brian C. Jones, Co-Chair
brian.jones@avon.com

Continuing Education Committee
Submitted by Nancy Monteiro-Riviere and Diane Heck

The committee met in San Francisco during the March 2001 meeting of the Society of Toxicology. During the meeting, plans for SOT 2002 were discussed including suggestions for potential CE Mini-courses. A course focusing on Models for the Study of Skin-Toxicant Interactions including:

a) Cell culture based systems
b) Artificial polymers and hybrid systems
c) Allograft and other animal models

It was decided that proposals for the inclusion of these in the 2002 SOT annual Meeting program would be submitted.

Diane A. Heck, Chair
dheck@eohsi.rutgers.edu
Nancy Monteiro-Riviere, Co-Chair
nancy_monteiro@ncsu.edu

Communications Committee
Submitted by Michael K. Robinson

The goal of the Communications Committee of the DTSS is to coordinate the collection and dissemination of information relevant to the needs of dermal toxicologists within the specialty section, as well as assisting the Council in outreach to the general toxicology community. We do so through the use of a specialty section newsletter and an SOT-linked web site.

The newsletter is published 3 times each year (currently March, July, and November) and contains reports from the president, committee updates, job postings, member news, member honors and awards, and member publications. The newsletter is sent to all members by email and is posted to the web site. The web site includes postings of the DTSS by-laws, current DTSS membership, current DTSS council members, special announcements, the annual report, a President's Corner, and the current and previous DTSS newsletters.

Michael K. Robinson, Chair
robinson.mk@pg.com
Lisa K. Ryan, Co-Chair
ryank@umdnj.edu

Regulatory/Policy Committee
Submitted by James N. McDougall and Robert W. Lange

The purpose of the Regulatory/Policy Committee is to promote awareness of issues, changes or initiatives that affect dermal toxicology in the areas of occupational, environmental and pharmaceutical regulations in the US, Europe and other regions. This committee is looking for individuals in the specialty section and the SOT as a whole who are familiar with regulations and policies of the main regulatory agencies to participate in this committee.

Dermal Toxicology Specialty Section
The intent of the committee is to raise the awareness of regulatory policies or issues that would impact on dermal specialty section members. We are also looking for suggestions for workshops or roundtables at the annual meeting that address regulatory topics.

The following is a list of useful regulatory web sites:

- International Regulatory Agencies/Organizations for Pharmaceuticals
- US Food and Drug Administration http://www.fda.gov/
- European Agency for the Evaluation of Medicinal Products http://www.emea.eu.int/
- International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use http://www.ifpma.org/ich1.html

**Interesting FDA Sites**

- FDA CDER updates (subscribe to receive) http://www.fda.gov/cder/cdernew/listservyv.html
- CDER freedom of information reading page http://www.fda.gov/cder/foi/index.htm
- IND content and format for Phase 1 studies 02-16-98, http://www.fda.gov/cder/guidance/phase1.pdf
- Summary: Higher or lower threshold levels for qualification of impurities may be appropriate for some individual drugs based on scientific rationale and level of concern, including drug class effects. The Impurities Decision Tree for generic drug substances (Atta)

**Skin Specific FDA Sites**

- Chronic Cutaneous Ulcer and Burn Wounds - Developing Products for Treatment
  - Summary: This document discusses several nonclinical pharmacology/toxicology issues that are inherent with the development of topical drugs that are intended to prevent sexually transmitted diseases (STD) or with the development of drugs proposed to act as vaginal treatments.

**Miscellaneous**

- James N. McDougal, Chair nmjames.mc doug al@wpafb.af.mil
- Robert W. Lange, Co-Chair mailto:mrwlange@mmm.com

**Methods Committee**

Submitted by Robert L. Bronaugh

The Methods Committee conducted a survey of DTSS members to determine their interests and experience in the development and validation of methods for dermal toxicity assessment. Nine members responded to the survey with their areas of interest. Skin irritation/mediators of irritation was the most cited area, with mention by five members. Percutaneous absorption and skin sensitization were tied for second place with four votes each. Our committee plans to develop a workshop (speakers - titles of presentations) to aid in the development, standardization and validation of one of the above methods. We would then propose this workshop to the DTSS program committee. We are also exploring the idea of utilizing the SOT web page to promote the sharing of technical expertise of DTSS members.

Robert L. Bronaugh, Chair rbronaug@cfsan.fda.gov
Elena A. Serbinova, Co-Chair prelest@ix.netcom.com

**Awards Committee**

During the past year, the Awards Committee worked with Dr. Anna Shvedova, the president of the DTSS, Avon Products Inc. and Bertek Pharmaceuticals to establish two student awards. The two awards established were for in vitro work (Avon) and in vitro/in vivo work (Bertek). The award notifications, guidelines for application and selection criteria were posted on the DTSS website. Student’s participants in the SOT who presented work relevant to dermal toxicology submitted their work that was evaluated by the Awards Committee. The winners of this year’s student awards were:

Valescia John: SOT DTSS-Avon Products Inc., 2001 Award for in vitro research
Ashley Murray: SOT DTSS-Bertek Pharmaceuticals 2001 Award for in vitro/in vivo research
Annette Santamaria: SOT DTSS-Bertek Pharmaceuticals 2001 Award for in vitro/in vivo Research

The Awards Committee together with Dr. Shvedova presented two additional certificates that recognized contributions to the administrative aspects of the SOT DTSS, which were especially important in the forming stages of our specialty section.

Sam A. Hart, Jr., 2001: Recognition certificate for outstanding DTSS support
Kelley A. Kathy: Recognition certificate for outstanding DTSS support

The committee prepared a report of its activities for the SOT meeting in March, 2001, San Francisco. Future goals of this committee include maintaining these awards for 2002 and developing a strategy to help share information related to jobs and careers in dermal toxicology.

Jeffery D. Laskin, Chair jlaskin@ehoi.rutgers.edu
Eugenia Harnagea-Theophilus, Co-Chair Eugenia.Theophilus@avon.com

**Program Committee**

Submitted by James E. Riviere

The DTSS is sponsoring a Symposium entitled “Altered Gene Expression and Cutaneous Toxicity” at the annual 2001 SOT meeting. This Symposium, co-chaired by DTSS officers Drs. G. Frank Gerberick and Ian Kimber will for the first time bring together experts in skin biology and cutaneous toxicity to review how characterization in changes in gene expression are providing new insights into mechanisms of toxicity and opportunities for new approaches to hazard assessment. Speakers include Drs. Rebecca Dearman, Emanuela...
Professor Kimber has contributed greatly to the ECETOC science programme for many years. Most recently he chaired the ECETOC Taskforce on Skin Sensitisation which produced two ECETOC reports (TR No. 78 Skin Sensitisation Testing: Methodological Considerations and Monograph No. 29 Skin Sensitisation Testing for the Purpose of Hazard Identification and Risk Assessment) and external publications. Currently he heads the ECETOC LRI Health Effects Monitoring Team.”

Congratulations, Ian! – eds.

**Member Publications**

**Each newsletter will feature a listing of specialty section member publications (journal articles, book chapters, books) that have appeared in print since the last edition. While the editors will do their best to survey the indexing services relative to the current membership roster, it is likely that some mistakes and omissions will occur. This is particularly true for books and book chapters. If we have inadvertently omitted a recent publication or listed something incorrectly, please advise us by email and we will see that this is corrected in the following newsletter. Also, we welcome your help in this endeavor. Please send us your citations for any recently published articles and books. That will aid us in our literature searching. Thank you - eds.**

**Recent Publications (DTSS authors in bold):**


- Lantz RC, Lemus R, Lange RW, Karol MH. Rapid reduction of intracellular...
glutathione in human bronchial epithelial
cells exposed to occupational levels of

Hamilton LM, Davies DE, Wilson SJ, 
Kimber I, Dearman RJ, Holgate ST. 
The bronchial epithelium in asthma--
much more than a passive barrier. 

Warbrick EV, Dearman RJ, Ashby J, 
Schmezer P, Kimber I. Preliminary 
assessment of the skin sensitizing 
activity of selected rodent carcinogens 
using the local lymph node assay. 

Rowland TL, McHugh SM, Deighton J, 
Ewan PW, Dearman RJ, Kimber I. 
Differential effect of thalidomide and 
dexmethasone on the transcription 

Dearman RJ, Kimber I Determination of 
protein allergenicity: studies in mice. 

Kimber I, Dearman RJ. Food allergy: 
what are the issues? Toxicol Lett. 120:165-170, 2001.

Cumberbatch M, Dearman RJ, 
Antonopoulos C, Groves RW, Kimber I. 
Interleukin (IL)-18 induces 
Langerhans cell migration by a tumour 
necrosis factor-alpha- and IL-1beta-

Griffiths CE, Cumberbatch M, Tucker SC, 
Dearman RJ, Andrew S, Headon DR, Kimber I. 
Exogenous topical lactoferrin inhibits 
allergen-induced Langerhans cell migration and cutaneous 

Steiling W, Basketter D, Berthold K, 
Butler M, Garrigue JL, Kimber I, Lea L, 
Newsome C, Roggeband R, Stropp G, 
Waterman S, Wiemann C. Skin 
sensitisation testing--new perspectives 

Dearman RJ, Kimber I Cytokine 
fingerprinting and hazard assessment 
of chemical respiratory allergy. J Appl 

Pichowski JS, Cumberbatch M, 
Dearman RJ, Basketter DA, Kimber I. 
Allergen-induced changes in interleukin 
1beta (IL-1 beta) mRNA expression by 
human blood-derived dendritic cells: 
inter-individual differences and 
relevance for sensitization testing. J 

Mizushima J, Kawasaki Y, Kitano T, 
Sakamoto K, Kawashima M, Cooke R, 
Maibach HI. Electron paramagnetic 
resonance study utilizing stripping 
method on normal human stratum 

Mizushima J, Kawasaki Y, Sakamoto K, 
Kawashima M, Cooke R, Maibach HI. 
Electron paramagnetic resonance: a new techniquin skin research. 

Zhai H, Brachman F, Pelosi A, 
Anigbogu A, Ramos MB, Torralba MC, 
Maibach HI. A bioengineering study on 
the efficacy of a skin protectant lotion in 

Maibach HI, Mathias CT. Allergic 
contact dermatitis from cycloaliphatic 
epoxide in jet aviation hydraulic fluid. 

Rietschel RL, Mathias CG, Taylor JS, 
Stoors EF, Sherertz EF, Pratt M, Marks 
JG Jr, Maibach HI. Fransway AF, 
Fowler JF Jr, DeLeo VA, Beltsio DV. 
A preliminary report of the occupation of 
patients evaluated in patch test clinics. 

Tanojo H, Maibach HI. Percutaneous 

Bashir SJ, Chew AL, Anigbogu A, 
Dreher F, Maibach HI. Physical and 
physiological effects of stratum corneum 

Yoshizawa Y, Tanojo H, Kim SJ, 
Maibach HI. Sea water or its 
components alter experimental irritant 

Charbonnier V, Morrison BM Jr, Paye M, 
Maibach HI. Subclinical, non-
erythematous irritation with an open 
assay model (washing); sodium lauryl 
sulfate (SLS) versus sodium laureth 

Zhai H, Maibach HI. Skin occlusion and 
irritant and allergic contact 
dermatitis: an overview. Contact 

Syed TA, Maibach HI. Butenafine 
hydrochloride: for the treatment of 
teridigital tinea pedis. Expert Opin 

He B, Munson AE, Meade BJ. 
Analysis of gene expression induced by 
irritant and sensitizing chemicals using 

Riviere JE, Smith CE, Budsaba K, 
Brooks JD, Oliagos EJ, Salem H, 
Monteiro-Riviere NA. Use of methyl 
salicylate as a simulant to predict the 
percutaneous absorption of sulfur 

Pinnell SR, Yang H, Omar M, 
Monteiro-Riviere NA, DeBuys HV, 
Walker LC, Wang Y, Levine M. Topical 
L-ascorbic acid; percutaneous absorption 

Ayres PH, Hayes JR, Higuchi MA, 
Mosberg AT, Sagartz JW. Subchronic 
inhalation by rats of mainstream smoke 
from a cigarette that primarily heats 
tobacco compared to a cigarette that 
burns tobacco. Inhal Toxicol. 13:149- 

Nyanda AM, Nunes MG, Ramesh A. A 
simple high-performance liquid 
chromatography method for the 
quantitation of tricyclic antidepressant 
drugs in human plasma or serum. J 

Andersen ME, Sarangapani R, Reitz RH, 
Gallavan RH, Dobrev JD, Plotzke KP. 
Physiological modeling reveals novel 
pharmacokinetic behavior for inhaled 
oxmethylycyclotetrasiloxane in rats. 

Robinson MK, McFadden JP, Basketter 
DA. Validity and ethics of the human 4-
h patch test as an alternative method to 
assess acute skin irritation potential. 

Schweigert MK, Mackenzie DP, Sarlo K. 
Occupational asthma and allergy 
associated with the use of enzymes in 
the detergent industry--a review of the 
epidemiology, toxicology and methods 

Price EO, Smith JR, Clark CR, Schlager 
JJ, Shih ML. MALDI-ToF/MS as a 
diagnostic tool for the confirmation of 
sulfur mustard exposure. J Appl 

Kagan VE, Kozlov AV, Tyurina YY, 
Shvedova AA, Yalovich JC. 
Antioxidant mechanisms of nitric oxide 
against iron-catalyzed oxidative stress in 

Singer T, Tinkle SS, Bader R, 
Schlegser C, Krebsfaenger N, Kalkuhl A, 
Monteiro-Antoine P, Weischedel T, 
Kalkuhl JG Jr, Singer TJ, Tinkle SS 
Tinkle SS. Innovative cell 
modeling: the use of human fibroblasts 
in the percutaneous absorption of a lipid 

Flint MS, Tinkle SS. C57bl/6 mice are 
resistant to acute restraint modulation of 

Maier LA, Sawyer RT, Tinkle SS, Kittle 
LA, Barker EA, Balkissoon R, Rose C,